Cardax (OTCQB: CDXI) is developing proprietary astaxanthin therapies for large unmet medical needs where oxidative stress and inflammation play important causative roles. Introduction Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration (“FDA”) Generally Recognized as Safe (“GRAS”) designation at certain doses. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding.
View Top Employees from Cardax, Inc.Website | http://www.cardaxpharma.com/ |
Ticker | CDXI |
Revenue | $1 million |
Funding | $3 million |
Employees | 16 (15 on RocketReach) |
Founded | 2006 |
Address | 2800 Woodlawn Dr Ste 129, Honolulu, Hawaii 96822, US |
Phone | (808) 457-1400 |
Fax | (808) 237-5901 |
Technologies |
JavaScript,
HTML,
PHP
+18 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Business Services General, Drug Discovery, Business Services, Pharmaceuticals |
Web Rank | 15 Million |
Keywords | What Is "Diluted Net Income", Astaxanthin In Pharmaceuticals |
Competitors | Constellation Pharmaceuticals, A MorphoSys Company, Inflazyme Pharmaceuticals Ltd., Karus Therapeutics Limited, KuDOS Pharmaceuticals, Rock Creek Pharmaceuticals, Inc |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular Cardax, Inc. employee's phone or email?
The Cardax, Inc. annual revenue was $1 million in 2024.
David Watumull is the President and CEO, Director of Cardax, Inc..
15 people are employed at Cardax, Inc..
Cardax, Inc. is based in Honolulu, Hawaii.
The NAICS codes for Cardax, Inc. are [325, 32541, 32, 3254].
The SIC codes for Cardax, Inc. are [283, 28].